NMDAE plus Placebo Cap
Sponsors
China Medical University Hospital
Conditions
Schizophrenia
Phase 2
Combination of NMDA-enhancing and Anti-inflammatory Treatments for Schizophrenia
RecruitingNCT04917302
Start: 2020-10-13End: 2026-12-31Target: 60Updated: 2025-02-19
Combination of NMDA-enhancing and Antioxidant Treatments for Schizophrenia
RecruitingNCT04959201
Start: 2020-11-30End: 2027-03-31Target: 90Updated: 2025-02-19
Combination of NMDA-enhancing and Anti-inflammatory Treatments for Ultra-resistant Schizophrenia
RecruitingNCT05240976
Start: 2022-02-23End: 2027-03-01Target: 80Updated: 2026-03-24